{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:13:15Z","timestamp":1770678795219,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,5,14]],"date-time":"2014-05-14T00:00:00Z","timestamp":1400025600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10557-014-6522-0","type":"journal-article","created":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T05:53:00Z","timestamp":1399960380000},"page":"331-334","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors: New among Antidiabetic Drugs"],"prefix":"10.1007","volume":"28","author":[{"given":"L. H.","family":"Opie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,14]]},"reference":[{"key":"6522_CR1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/hrt.2010.214031","volume":"97","author":"LH Opie","year":"2011","unstructured":"Opie LH, Yellon DM, Gersh BJ. Controversies in the cardiovascular management of type 2 diabetes. Heart. 2011;97:6\u201314.","journal-title":"Heart"},{"key":"6522_CR2","volume":"11","author":"B Hemmingsen","year":"2013","unstructured":"Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;11, CD008143.","journal-title":"Cochrane Database Syst Rev"},{"key":"6522_CR3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","volume":"154","author":"WL Bennett","year":"2011","unstructured":"Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602\u201313.","journal-title":"Ann Intern Med"},{"key":"6522_CR4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4093\/dmj.2013.37.6.465","volume":"37","author":"YK Lee","year":"2013","unstructured":"Lee YK, Song SO, Kim KJ, et al. Glycemic effectiveness of metformin-based dual-combination therapies with sulphonylurea, pioglitazone, or DPP4-Inhibitor in drug-na\u00efve Korean type 2 diabetic patients. Diabetes Metab J. 2013;37:465\u201374.","journal-title":"Diabetes Metab J"},{"key":"6522_CR5","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(10)60307-8","volume":"375","author":"RE Pratley","year":"2010","unstructured":"Pratley RE, Nauck M, Bailey T, et al. 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447\u201356.","journal-title":"Lancet"},{"key":"6522_CR6","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","volume":"375","author":"M Diamant","year":"2010","unstructured":"Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375:2234\u201343.","journal-title":"Lancet"},{"key":"6522_CR7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.clinthera.2011.09.028","volume":"33","author":"KR Richard","year":"2011","unstructured":"Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33:1609\u201329.","journal-title":"Clin Ther"},{"key":"6522_CR8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.vph.2011.05.001","volume":"55","author":"GP Fadini","year":"2011","unstructured":"Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vasc Pharmacol. 2011;55:10\u20136.","journal-title":"Vasc Pharmacol"},{"key":"6522_CR9","doi-asserted-by":"crossref","unstructured":"Ghezzi C, Wright EM. Regulation of the human Na+-dependent glucose cotransporter hSGLT2.. Am J Physiol Cell Physiol. 2012 Aug 1. PMID 22673616.","DOI":"10.1152\/ajpcell.00115.2012"},{"key":"6522_CR10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0005-2736(84)90421-8","volume":"777","author":"JT Lin","year":"1984","unstructured":"Lin JT, Szwarc K, Kinne R, Jung CY. Structural state of the Na+\/D-glucose cotransporter in calf kidney brush-border membranes. Target size analysis of Na+-dependent phlorizin binding and Na+-dependent D-glucose transport. Biochim Biophys Acta. 1984;777:201\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"6522_CR11","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/meta.2000.7729","volume":"49","author":"T Adachi","year":"2000","unstructured":"Adachi T, Yasuda K, Okamoto Y, et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism. 2000;49:990\u20135.","journal-title":"Metabolism"},{"key":"6522_CR12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","volume":"320","author":"K Katsuno","year":"2007","unstructured":"Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. Pharmacol Exp Ther. 2007;320:323\u201330.","journal-title":"Pharmacol Exp Ther"},{"key":"6522_CR13","unstructured":"Ryd\u00e9n L, Grant PJ. ESC Pocket Guidelines, version 2013. Committee for Practice Guidelines. European Association for the Study of Diabetes and European Society of Cardiology. Guidelines on diabetes, pre-diabetes and cardiovascular diseases, 2013, page 17. www.escardioi.org\/guidelines ."},{"key":"6522_CR14","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryd\u00e9n","year":"2013","unstructured":"Ryd\u00e9n L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035\u201387.","journal-title":"Eur Heart J"},{"key":"6522_CR15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s13300-011-0003-2","volume":"2","author":"GF Carlson","year":"2011","unstructured":"Carlson GF, Tou CK, Parikh S, Birmingham BK, Butler K. Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT\/QTc study. Diabetes Ther. 2011;2:123\u201332.","journal-title":"Diabetes Ther"},{"key":"6522_CR16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.clinthera.2013.06.009","volume":"35","author":"W Zhang","year":"2013","unstructured":"Zhang W, Smulders R, Abeyratne A, et al. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study. Clin Ther. 2013;35:1150\u201361.","journal-title":"Clin Ther"},{"key":"6522_CR17","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1463-1326.2012.01624.x","volume":"14","author":"RA Smulders","year":"2012","unstructured":"Smulders RA, Zhang W, Veltkamp SA, et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes Metab. 2012;14:937\u201343.","journal-title":"Diabetes Obes Metab"},{"key":"6522_CR18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenl\u00f6f","year":"2013","unstructured":"Stenl\u00f6f K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372\u201382.","journal-title":"Diabetes Obes Metab"},{"key":"6522_CR19","doi-asserted-by":"crossref","unstructured":"Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2013 Nov 14. doi: 10.1111\/dom.12239 . [Epub ahead of print].","DOI":"10.1111\/dom.12239"},{"key":"6522_CR20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","volume":"36","author":"L Ji","year":"2014","unstructured":"Ji L, Ma J, Li H, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014;36:84\u2013100.","journal-title":"Clin Ther"},{"key":"6522_CR21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","volume":"159","author":"D Vasilakou","year":"2013","unstructured":"Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262\u201374.","journal-title":"Ann Intern Med"},{"key":"6522_CR22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","volume":"27","author":"KM Johnsson","year":"2013","unstructured":"Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27:473\u20138.","journal-title":"J Diabetes Complicat"},{"key":"6522_CR23","doi-asserted-by":"crossref","unstructured":"Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29:163\u20137712.","DOI":"10.1007\/s12325-011-0098-x"},{"key":"6522_CR24","doi-asserted-by":"crossref","unstructured":"Reilly TP, Graziano MJ, Janovitz EB, et al. Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an Inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2014 Jan 29. [Epub ahead of print].","DOI":"10.1007\/s13300-014-0053-3"},{"key":"6522_CR25","doi-asserted-by":"crossref","unstructured":"Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med. 2013 May;125(3):181\u20139.","DOI":"10.3810\/pgm.2013.05.2667"},{"key":"6522_CR26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.dsx.2012.08.003","volume":"6","author":"HW Chan","year":"2012","unstructured":"Chan HW, Ashan B, Jayasekera P, Collier A, Ghosh S. A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: \u2018glucuretics\u2019. Diabetes Metab Syndr. 2012;6:224\u20138.","journal-title":"Diabetes Metab Syndr"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-014-6522-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-014-6522-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-014-6522-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T11:35:10Z","timestamp":1565436910000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-014-6522-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,14]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["6522"],"URL":"https:\/\/doi.org\/10.1007\/s10557-014-6522-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,14]]}}}